Equities

V3V

DE000A0BL849

Healthcare Facilities & Services

Market Closed - Xetra Other stock markets 09:06:16 03/07/2024 pm IST			5-day change	1st Jan Change
4.5 ^EUR	+0.45%		-0.44%	-14.12%

01/06	VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/04	VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Vita 34 AG Announces Board Changes

August 01, 2014 at 09:57 pm IST

The supervisory board of Vita 34 AG elected Dr. Hans-Georg Giering, so far vice chairman of the supervisory board, as the new chairman. He takes over the position from Dr. Holger F-disch with immediate effect. Dr. F-disch will continue to actively support the corporation as vice chairman of the supervisory board in the future.

Latest news about VITA 34 AG

VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2024	01/06	CI
VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2023	30/04	CI
VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	24/11	CI
VITA 34 AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	01/23/01	CI
VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2023	01/23/01	CI
Vita 34 Starts Patient Enrollment in Phase 1 Trial of CAR-T Drug Candidate	12/23/12	MT
Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug Candidate	12/23/12	CI
VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
VITA 34 AG Provides Revenue Guidance for the Financial Year 2023	25/23/25	CI
VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/22/22	CI
VITA 34 AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	31/22/31	CI
VITA 34 AG Revises Earnings Guidance for the Financial Year 2022	30/22/30	CI
VITA 34 AG Announces Dirk Plaga Will Accordingly Assume the Position of Chief Financial Officer of the Company	29/22/29	CI
VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2022	01/22/01	CI
VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2021	01/22/01	CI
Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022	30/22/30	CI
Vita 34 Names New Chair, Appoints Chief Commercial Officer	21/22/21	MT
Vita 34 AG Announces Change in the Chair of the Management Board	19/22/19	CI
VITA 34 AG completed the acquisition of Polski Bank Komórek Macierzystych S.A from from AOC Health GmbH, Jakub Baran, Tomasz Baran and others.	15/21/15	CI
VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	11/21/11	CI
Vita 34 AG Announces Withdrawal of Guidance for Financial Year 2021	09/21/09	CI
Vita 34 : Commences Offer Period for Polski Bank Komorek Takeover	20/21/20	MT
VITA 34 AG Affirms Earnings Guidance for the Full Fiscal Year 2021	31/21/31	CI
VITA 34 AG Reports Earnings Results for the Second Quarter Ended June 30, 2021	31/21/31	CI
Vita 34 : Names New CFO	16/21/16	MT

Chart VITA 34 AG

Duration

Period

More charts

Company Profile

Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the childâs birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The Company acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.

Sector

Healthcare Facilities & Services

Calendar

30/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for VITA 34 AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.48 EUR

Average target price

6 EUR

Spread / Average Target

+33.93%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
VITA 34 AG	-14.12%	83.85M
HCA HEALTHCARE, INC.	+20.64%	83.73B
CVS HEALTH CORPORATION	-28.19%	72.21B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.35%	26.2B
FRESENIUS SE & CO. KGAA	+1.39%	17.18B
LABCORP HOLDINGS INC.	-10.31%	17.09B
QUEST DIAGNOSTICS INCORPORATED	+2.19%	15.18B
NATERA, INC.	+78.22%	13.59B
TENET HEALTHCARE CORPORATION	+79.75%	13.11B
PURE HEALTH HOLDING	-22.98%	12.92B

Other Healthcare Facilities & Services